Evidence map›Paper›PMID 9326322›Full record

ArticleAmerican journal of human genetics1997

Analysis of the RPGR gene in 11 pedigrees with the retinitis pigmentosa type 3 genotype: paucity of mutations in the coding region but splice defects in two families.

R Fujita, M Buraczynska, L Gieser, W Wu, P Forsythe, M Abrahamson, S G Jacobson, P A Sieving, S Andréasson, A Swaroop

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 64 citations in OpenAlex.

  1. Genotype-Phenotype Analysis ofFrontiers in genetics · 2021
    Article
  2. Article
  3. Article
  4. Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Gene therapeutic approach using mutation-adapted U1 snRNA to correct a RPGR splice defect in patient-derived cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

R FujitaDepartment of Ophthalmology, University of Michigan, Ann Arbor 48105, USA.
M Buraczynska
L Gieser
W Wu
P Forsythe
M Abrahamson
S G Jacobson
P A Sieving
S Andréasson
A Swaroop
University of Michigan–Ann Arbor · USW.K. Kellogg Foundation · USLund University · SE

Funding

X-LINKED RETINITIS PIGMENTOSAR01EY007961 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, HEMANT · 1994 to 2009
$4.3M
PHENOTYPES OF RETINITIS PIGMENTOSA RHODOPSIN MUTATIONSR01EY005627 · NEI · UNIVERSITY OF PENNSYLVANIA · PI JACOBSON, SAMUEL G · 1986 to 2001
$596k
X-LINKED OCULAR ALBINISM &RETINITIS PIGMENTOSAR29EY007961 · NEI · YALE UNIVERSITY · PI SWAROOP, ANAND · 1989 to 1993
–
NEI NIH HHS EY05627NEI NIH HHS EY07003NEI NIH HHS EY07961
6 · The paper itself

Abstract

X-linked retinitis pigmentosa (XLRP) is a severe form of inherited progressive retinal degeneration. The RP3 (retinitis pigmentosa type 3) locus at Xp21.1 is believed to account for the disease in the majority of XLRP families. Linkage analysis and identification of patients with chromosomal deletion have refined the location of the RP3 locus and recently have led to the cloning of the RPGR (retinitis pigmentosa GTPase regulator) gene, which has been shown to be mutated in 10%-15% of XLRP patients. In order to systematically characterize the RPGR mutations, we identified 11 retinitis pigmentosa type III (RP3) families by haplotype analysis. Sequence analysis of the PCR-amplified genomic DNA from patients representing these RP3 families did not reveal any causative mutation in RPGR exons 2-19, spanning >98% of the coding region. In patients from two families, we identified transition mutations in the intron region near splice sites (IVS10+3 and IVS13-8). RNA analysis showed that both splice-site mutations resulted in the generation of aberrant RPGR transcripts. Our results support the hypothesis that mutations in the reported RPGR gene are not a common defect in the RP3 subtype of XLRP and that a majority of causative mutations may reside either in as yet unidentified RPGR exons or in another nearby gene at Xp21.1.

Indexed as

Eye ProteinsAdultCarrier ProteinsExonsFemaleGenes, RegulatorGenetic LinkageGenetic MarkersGenotypeHaplotypesHeterozygoteHumansMaleMutationPedigreePolymorphism, GeneticCarrier ProteinsEye ProteinsGenetic MarkersRNA, MessengerRPGR protein, human

Identifiers

PMID9326322
PMCPMC1715956
OpenAlexW2033449460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.